Trial record 1 of 1 for:    11-C-0100
Previous Study | Return to List | Next Study

Gemcitabine and CT-011 for Resected Pancreatic Cancer

This study has suspended participant recruitment.
(Pidilizumab (CT-011) licensing transfer; Pending Medivation Inc. review.)
Sponsor:
Information provided by (Responsible Party):
Samir N. Khleif, Georgia Regents University
ClinicalTrials.gov Identifier:
NCT01313416
First received: March 10, 2011
Last updated: July 15, 2015
Last verified: April 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: February 2018
  Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)